A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy
NCT ID: NCT02111824
Last Updated: 2021-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
7 participants
INTERVENTIONAL
2014-01-05
2019-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunomagnetic Detection of Cancer Cells in Pleural Effusion in Lung Cancer Patients as Additional Staging and Prognostic Tool
NCT02172027
Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study
NCT04987281
Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung Cancer
NCT02423148
A Multi-Center Trial of the ProLung Test™
NCT01566682
Non-linear Multimodal Microendoscopy for Lung Cancer Pathology
NCT02699229
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
If the patient agrees to take part in this study, the following information about their routine standard of care lung biopsy will be collected:
The accuracy of the procedure How long it takes to complete the procedure How long the needle is inserted to collect the biopsy sample The number of CT scans used during the procedure The radiation dose level used Any complications and/or side effects the patient may experience The results of the diagnosis from the biopsy sample Researchers will take appropriate steps to keep the patient's information private. However, there is no guarantee of absolute privacy. The patient's information will be kept in a password-protected computer at MD Anderson for up to 7 years and will only be permitted to be viewed by the study doctor and members of the research staff.
During the patient's routine lung biopsy, the doctor will use the MIMIG intervention system to help guide the needle for the biopsy the lung biopsy.
Length of Study:
The patient's active participation on this study will be over after the lung biopsy procedure is over.
Description of Procedure:
The first CT scan will be used as a map to guide a needle into the tumor with the MIMIG intervention system. After that, a second CT scan will be done to confirm that the needle tip has been properly inserted inside the lung tumor. Based on the results from these images, the tumor will then be biopsied the same way it would be as part of normal routine care.
This is an investigational study. The use of the MIMIG intervention system to help guide the needle for the lung biopsy is not FDA approved or commercially available. The use of the MIMIG intervention system is investigational.
Up to 24 patients will take part in this study. All will be enrolled at MD Anderson.
Group 3:
If the patient agrees to take part in this study, the following information about the patient's routine standard of care lung biopsy will be collected:
The accuracy of the procedure How long it takes to complete the procedure How long the needle is inserted to collect the biopsy sample The number of CT scans used during the procedure The radiation dose level used Any complications and/or side effects the patient may experience The results of the diagnosis from the biopsy sample Researchers will take appropriate steps to keep the patient's information private. However, there is no guarantee of absolute privacy. The patient's information will be kept in a password-protected computer at MD Anderson and will only be permitted to be viewed by the study doctor and members of the research staff.
During the patient's routine lung biopsy, the doctor will use the MIMIG intervention system to help guide the needle for the biopsy the lung biopsy. The patient will also have an intravenous (IV) needle placed in the patient's vein to give the patient indocyanine green (IC-Green). IC-Green is a dye that allows researchers to see the patient's veins and other organs during the biopsy.
Length of Study:
After the lung biopsy is complete, the patient's active participation on this study will be over.
Description of Procedure:
The first CT scan will be used as a map to guide a needle into the tumor with the MIMIG intervention system. After that, a second CT scan will be done to confirm that the needle tip has been properly inserted inside the lung tumor. A fiberoptic endoscope (a small camera with a light) will be inserted through the CT guided needle to the tumor to help doctors see the tumor blood vessels. IC-Green will also be given by IV to allow doctors to see the blood vessels of the tumor. Based on the results from these images, the tumor will then be biopsied the same way it would be as part of normal routine care.
This is an investigational study. The use of the MIMIG intervention system to help guide the needle for the lung biopsy is not FDA approved or commercially available. The use of the MIMIG intervention system is investigational. The use of fiberoptic endoscope for lung tumor vessels imaging is not FDA approved or commercially available. The use of fiberoptic endoscope is investigational. The use of IC-Green in combination with fiberoptic endoscope for lung tumor vessels imaging is not FDA approved or commercially available. The use of IC-Green in combination with fiberoptic endoscope is investigational.
Up to 24 patients will take part in this study. All will be enrolled at MD Anderson.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 2
During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the the lung biopsy.
MIMIG System
Minimally Invasive MultiModality Imaging Guidance System (MIMIG)
Group 3
During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the lung biopsy. An intravenous (IV) needle placed in the vein to give indocyanine green (IC-Green). Fiber Optic camera will be used to view tissue before biopsy via insertion catheter.
MIMIG System
Minimally Invasive MultiModality Imaging Guidance System (MIMIG)
Indocyanine Green (ICG)
Use of ICG as staining for fiberoptic visualization of lung tissue via introducer needle prior to obtaining tissue samples.
Group 1
Control Group consists of twelve patients who have undergone biopsy of a peripheral lung lesion by using repetitive CT-guidance. Review of medical records only, no further intervention.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MIMIG System
Minimally Invasive MultiModality Imaging Guidance System (MIMIG)
Indocyanine Green (ICG)
Use of ICG as staining for fiberoptic visualization of lung tissue via introducer needle prior to obtaining tissue samples.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. Ability to understand and willingness to sign Informed Consent Document (ICD)
Exclusion Criteria
* Pregnant or nursing females.
* Known allergy to iodine or intravenous contrast agent.
* Known allergy or anaphylactic reaction to indocyanine green (ICG).
* Patients with renal dysfunction (GFR \<60) or patients on dialysis
* Patients with liver dysfunction: total bilirubin \> 2.5 mg/dl; albumin \< 2.5 mg/dl; alanine aminotransferase (ALT), aspartate aminotransferase (AST) \> 5 times upper limits of normal
* Uncorrectable coagulopathy prohibiting biopsy. (INR \> 1.5 and/ or platelets \< 50,000)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
The Methodist Hospital Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stephen T. Wong, PhD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alda Tam, MD
Role: PRINCIPAL_INVESTIGATOR
MD Anderson Cancer Center Interventional Radiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MD Anderson Cancer Center Interventional Radiology Dept.
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00009873
Identifier Type: -
Identifier Source: org_study_id
NCT01433822
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.